Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. The Lancet. Oncology

Birgit Geoerger, C. Michel Zwaan, Lynley V. Marshall, Jean Michon, Franck Bourdeaut, Michela Casanova, Nadège Corradini, Gianluca Rossato, Mufiza Farid-Kapadia, Colby S. Shemesh, Katherine E. Hutchinson, Francis Donaldson, Minlei Liao, Hubert Caron, Tanya Trippett

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Atezolizumab is an inhibitor of PD-L1, which can lead to enhanced anticancer T-cell activity. We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in children and young adults with refractory or relapsed solid tumours, with known or expected PD-L1 expression. METHODS: iMATRIX was a multicentre, open-label, phase 1-2 trial of patients (aged
Original languageEnglish
Pages (from-to)134-144
Number of pages11
JournalThe Lancet Oncology
Volume21
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • Adult
  • Female
  • Humans
  • Male
  • Child
  • Child, Preschool
  • Follow-Up Studies
  • Adolescent
  • Prognosis
  • Young Adult
  • Antineoplastic Agents/*therapeutic use
  • Tissue Distribution
  • Antibodies, Monoclonal, Humanized/*therapeutic use
  • Hodgkin Disease/*drug therapy/pathology
  • Lymphoma, Non-Hodgkin/*drug therapy/pathology
  • Maximum Tolerated Dose
  • Neoplasms/*drug therapy/pathology

Fingerprint Dive into the research topics of 'Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. The Lancet. Oncology'. Together they form a unique fingerprint.

Cite this